A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)
This study was to compare the effect of 156 weeks of treatment with MK-0966 (Rofecoxib) versus placebo on the recurrence of colorectal adenomas (growths that occur on the inside (the lining) of the large intestine, also known as the colon) in patients with a history of colorectal adenomas.
Colorectal Adenoma
DRUG: MK0966; Rofecoxib / Duration of Treatment: 156 weeks|DRUG: Placebo/ Duration of Treatment: 156 weeks
Cumulative colorectal adenoma recurrence during treatment in patients with an increased risk to develop colorectal cancer., 156 Weeks
Cumulative colorectal adenoma recurrence during treatment in patients with a history of colorectal adenoma, 156 Weeks|Cumulative colorectal adenoma recurrence during treatment in all patients, 52 Weeks|To evaluate safety & tolerability of rofecoxib
This study was to compare the effect of 156 weeks of treatment with MK-0966 (Rofecoxib) versus placebo on the recurrence of colorectal adenomas (growths that occur on the inside (the lining) of the large intestine, also known as the colon) in patients with a history of colorectal adenomas.